goodmen

The Swedish pharma and life sciences litigation newsletter SEPTEMBER 2024 IN THIS ISSUE PHARMA Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products There is ongoing intense litigation in Sweden between Bayer and several generic companies concerning Bayer’s blockbuster product Xarelto, an anticoagulant used to prevent and treat blood clots. The dispute began

JANUARY 2024 The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE PHARMA Biogen v Sandoz, Viatris, and Neuraxpharm over dimethyl fumarate products Biogen continues to achieve success in enforcing its patent against dimethyl fumarate products from Sandoz, Viatris, and Neuraxpharm, also successfully defending against the validity challenge. We reported on this case earlier

The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE PHARMA Novartis v Zentiva, Glenmark, Mylan and Teva over fingolimod products Novartis’ pursuit of preliminary injunctions against generic fingolimod products continues. We reported in our newsletters in June and December 2022 about Novartis’ patent infringement actions under EP 2 959 894 against competitors’ fingolimod

The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE PHARMA Update on Novartis v Zentiva, Glenmark, Teva, and Mylan over fingolimod products We have written about this case before in the June 2022 issue. Novartis is pursuing infringement proceedings against competitors’ fingolimod products based on its patent EP 2 959 894 relating to

The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE Peter KenametsPartner, Attorney-at-lawLind.Edlund.Kenamets. Fredrik LüningPartner, Attorney-at-lawLind.Edlund.Kenamets PHARMA Novartis v Zentiva over generic fingolimod product Novartis is adopting an innovative approach to preliminary injunction (PI) proceedings in Sweden. They pursue proceedings against Zentiva for infringement of EP 2 959 894 (S1P receptor modulators for treating